LifeMD, Inc. (NASDAQ: LFMD) reported second quarter 2026 revenue of $47.3 million, down from $49.0 million in the second quarter of 2025, as the virtual primary care provider navigates a strategic transition away from compounded GLP-1 medications toward branded therapies. The company posted an adjusted EBITDA loss of approximately $3.5 million, reversing from positive adjusted EBITDA of approximately $3.9 million in the prior-year period, reflecting elevated customer acquisition costs and the impact of a $39 introductory offer on upfront cash collections. Despite the near-term profitability pressure, gross margin expanded by approximately 280 basis points year-over-year to approximately 89%, supported by lower shipping and fulfillment costs and the scaling of its in-house pharmacy.

The results underscore a deliberate trade-off between short-term earnings and long-term subscriber value. LifeMD’s total active subscriber base grew 20% year-over-year to approximately 356,000, with Weight Management Program subscribers reaching approximately 108,000 at quarter end. Approximately 95% of new weight management patients now begin treatment with branded GLP-1 therapies, signaling the near-completion of the transition away from compounded alternatives. This shift has altered revenue dynamics; while revenue declined, gross profit remained essentially flat at $42.0 million compared to the prior-year period, indicating that higher-margin branded products are offsetting volume declines in compounded offerings.

Operating expenses showed signs of stabilization, with selling and marketing expenses declining $1.8 million sequentially to $28.0 million, consistent with management’s planned step-down in patient acquisition spend. General and administrative expenses fell 5% year-over-year to $13.6 million, led by reductions in employee expenses and legal fees. GAAP net loss attributable to common stockholders widened to $7.9 million, or $0.16 per share, from $3.8 million, or $0.09 per share, in the prior-year period, largely due to the operational losses before non-cash adjustments and preferred stock dividends.

Strategic Initiatives and Partnerships

LifeMD launched an exclusive telehealth co-marketing collaboration with Halozyme’s wholly-owned subsidiary, Antares Pharma, Inc., for XYOSTED™, the only FDA-approved once-weekly subcutaneous testosterone auto-injector. Chairman and CEO Justin Schreiber noted that the company is reshaping its business around longer-duration members, branded therapies, pharmacy services, and insurance partnerships. Following pricing changes in weight management, the share of new patients selecting multi-month packages increased from approximately 25% to approximately 85%, a move intended to improve retention and lifetime value.

Women’s Health operating trends also improved, with lower customer acquisition costs and new pharmacy products launching in the second half. The company exited the quarter with $25.1 million in cash, no debt, and $30 million in additional liquidity under its revolving credit facility. CFO Atul Kavthekar highlighted that the recurring rebill base now represents approximately 84% of revenue, serving as the profit engine funding growth.

Financial Guidance Revision

Management revised full-year 2026 guidance, lowering the revenue outlook to $205.5 million to $212.5 million from previous guidance of $220 million to $230 million. Adjusted EBITDA guidance was cut to negative $6.0 million to breakeven, down from previous guidance of $12 million to $17 million, incorporating $2 million to $3 million of net launch costs for XYOSTED™. For the third quarter of 2026, LifeMD expects revenue between $48 million and $51 million, with adjusted EBITDA ranging from negative $1 million to positive $2 million. The company projects an annualized exit revenue run rate of approximately $250 million and approximately $22 million of annualized adjusted EBITDA by the fourth quarter of 2026.

What the Numbers Show

The divergence between stable gross profit and declining revenue highlights the margin expansion benefit of shifting to branded GLP-1s, which command higher prices despite potentially lower volumes than compounded drugs. However, the widening adjusted EBITDA loss indicates that customer acquisition costs have not yet fully normalized to support this higher-margin mix. The sequential decline in selling and marketing expenses suggests that the cost structure is adjusting, but the impact of the $39 introductory offer on cash collections remains a headwind in the near term. The high proportion of recurring revenue (84%) provides a cushion against volatility, but the company’s path to profitability depends on sustaining the shift toward multi-month packages and reducing reliance on paid media.

LifeMD (NASDAQ: LFMD) has released its third-quarter revenue guidance, projecting sales between $48.000 million and $51.000 million. This forecast represents a notable deviation from market expectations, falling short of the $58.547 million analyst estimate. The gap between the upper end of the company’s guidance and the consensus estimate suggests potential operational headwinds or slower-than-anticipated demand in its core markets during the period.

The company’s guidance indicates a revenue range that is approximately $7.5 million to $10.5 million below the expected figure. For investors tracking performance against benchmarks, this miss highlights a divergence between management’s internal outlook and external analyst models. The specific drivers behind this variance were not detailed in the brief filing, but the magnitude of the difference underscores the importance of upcoming earnings disclosures for clarity on margin impacts and cost structures.

Key Financial Metrics

What the Numbers Show

The primary analytical takeaway from this guidance is the substantial variance from consensus. With the high end of LifeMD’s guidance at $51.000 million, the company is projecting a shortfall of roughly 12.9% against the $58.547 million estimate. Such a discrepancy typically prompts investors to scrutinize whether the miss stems from top-line volume issues, pricing pressures, or delayed recognition of revenue. Until further details are provided in the full earnings report, the market will likely focus on whether this guidance reflects a temporary seasonal dip or a more structural shift in growth trajectory.